Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 30 April 2026, indicating stable share capital and no equity movements during the month.

Authorised and Registered Capital • H-share authorisation remained at 154.33 million shares with a par value of RMB0.2, translating to authorised capital of RMB30.87 million. • Domestic share authorisation stayed at 171.65 million shares at the same par value, equivalent to RMB34.33 million. • Combined authorised capital therefore held steady at RMB65.20 million.

Issued Shares and Treasury Position • Issued H shares closed the month unchanged at 154.33 million, with no treasury shares outstanding. • Issued domestic shares likewise remained at 171.65 million, also with zero treasury shares. • The company recorded no share issues, cancellations, repurchases, options, warrants, convertibles, or other equity adjustments.

Public Float Status • Bao Pharma confirmed compliance with the Hong Kong Stock Exchange’s 25 % minimum public-float requirement for its H-share class as at 30 April 2026.

Governance Confirmation • Executive Director Liu Yanjun affirmed that all statutory filings and regulatory conditions associated with the issuer’s securities remain fully satisfied.

The April 2026 filing underscores Bao Pharma’s stable capital structure, with no dilution or concentration events reported for the month.